Study wrapper · #241
Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.
Editor's note
An analytical-method paper aimed at anti-doping labs, classified as in-vitro/method development. The team validated an immunoaffinity-purification plus high-resolution mass-spectrometry assay to detect four GHRH analogues — sermorelin, CJC-1293, CJC-1295, and tesamorelin — plus two metabolites in human plasma. This is detection science, not efficacy or safety research: it tells us these peptides can be captured and identified at sub-50 pg/mL levels, and that metabolite patterns differed between rats and a human sample, flagging species differences the authors say require further work. Tesamorelin, the only FDA-approved compound in the set (for HIV-associated lipodystrophy), and sermorelin, a former approved drug, appear here purely as analytical targets. For readers, the note is that these peptides are prohibited in sport and detectable, and that rodent metabolism doesn't cleanly predict human metabolism. It carries no clinical implications for any indication.
Plain-language abstract
This paper describes a laboratory test developed to detect growth-hormone-releasing hormones (GHRHs) in blood, because these substances are banned in sport. GHRHs prompt the body to release its own growth hormone. The researchers built a method that first uses antibodies to pull the target peptides out of plasma, then separates and identifies them with high-resolution mass spectrometry. The test was designed to spot four of these drugs at once — Geref (sermorelin), CJC-1293, CJC-1295, and Egrifta (tesamorelin) — plus two breakdown products. It was fully validated and could detect the peptides at very low concentrations (under 50 picograms per millilitre). To study how the drugs break down, the team gave single GHRHs to rats and also examined a plasma sample from one healthy man given sermorelin by injection under the skin. All the intact drugs were still detectable for at least four hours, but a breakdown product expected from the rat work only showed up in the human sample — highlighting that animals and humans process these drugs differently. The authors say more work is needed before the method is fully reliable for testing. The study is about detection only, not about whether these drugs help or are safe.